To check the presence, in addition to the EIF6 variant, of any other variants in genes involved in MDS or AML (Lindsley, 2017; Steensma, 2017; Armstrong et al., 2018; Bluteau et al., 2018; Obrochta and Godley, 2018; Kennedy et al., 2021), we analyzed the exome file of UPN 2 and three genes, ASXL1, JAK2, and GNAS, were identified as bearing a mutation which might be relevant for the risk of MDS/AML (Table1). This evidence concerns the gene ASXL1 and myelodysplastic syndrome.